Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ADVANCED SOLID TUMORS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 45 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Mathijssen, RHJ; van Alphen, RJ; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
      Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)

      CLINICAL CANCER RESEARCH
    2. Laurie, SA; Pfister, DG; Kris, MG; Tong, WP; Chronowski, G; Pisters, KWM; Heelan, RT; Sirotnak, FM
      Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin

      CLINICAL CANCER RESEARCH
    3. Smorenburg, CH; Sparreboom, A; Bontenbal, M; Verweij, J
      Combination chemotherapy of the taxanes and antimetabolites: its use and limitations

      EUROPEAN JOURNAL OF CANCER
    4. Schilder, RJ; Gallo, JM; Millenson, MM; Bookman, MA; Weiner, LM; Rogatko, A; Rogers, B; Padavic-Shallers, K; Boente, M; Rosenblum, N; Adams, AL; Ciccotto, S; Ozols, RF
      Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy

      JOURNAL OF CLINICAL ONCOLOGY
    5. de Jongh, FE; Verweij, J; Loos, WJ; de Wit, R; de Jonge, MJA; Planting, AST; Nooter, K; Stoter, G; Sparreboom, A
      Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

      JOURNAL OF CLINICAL ONCOLOGY
    6. Hartung, G
      New developments in chemotherapy of gastrointestinal carcinomas

      ONKOLOGIE
    7. Heath, EI; O'Reilly, S; Humphrey, R; Sundaresan, P; Donehower, RC; Sartorius, S; Kennedy, MJ; Armstrong, DK; Carducci, MA; Sorensen, JM; Kumor, K; Kennedy, S; Grochow, LB
      Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    8. Seymour, L; Eisenhauer, E
      A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    9. Cunningham, D; Coleman, R
      New options for outpatient chemotherapy - the role of oral fluoropyrimidines

      CANCER TREATMENT REVIEWS
    10. Margolin, K; Longmate, J; Synold, TW; Gandara, DR; Weber, J; Gonzalez, R; Johansen, MJ; Newman, R; Baratta, T; Doroshow, JH
      Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium

      INVESTIGATIONAL NEW DRUGS
    11. Vigano, L; Locatelli, A; Grasselli, G; Gianni, L
      Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy

      INVESTIGATIONAL NEW DRUGS
    12. Shah, MA; Schwartz, GK
      The relevance of drug sequence in combination chemotherapy

      DRUG RESISTANCE UPDATES
    13. Enzinger, PC; Ilson, DH
      Irinotecan in esophageal cancer

      ONCOLOGY-NEW YORK
    14. Dutcher, JP; Novik, Y; O'Boyle, K; Marcoullis, G; Secco, C; Wiernik, PH
      20th-century advances in drug therapy in oncology - Part II

      JOURNAL OF CLINICAL PHARMACOLOGY
    15. Markman, M; Blessing, JA; Alvarez, RD; Hanjani, P; Waggoner, S; Hall, K
      Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

      GYNECOLOGIC ONCOLOGY
    16. Ford, HER; Cunningham, D; Ross, PJ; Rao, S; Aherne, GW; Benepal, TS; Price, T; Massey, A; Vernillet, L; Gruia, G
      Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma

      BRITISH JOURNAL OF CANCER
    17. Bleiberg, H
      CPT-11 in gastrointestinal cancer

      EUROPEAN JOURNAL OF CANCER
    18. Twelves, C
      UFT plus calcium folinate/irinotecan in colorectal cancer

      ONCOLOGY-NEW YORK
    19. DeVore, RF; Johnson, DH; Crawford, J; Garst, J; Dimery, IW; Eckardt, J; Eckhardt, SG; Elfring, GL; Schaaf, LJ; Hanover, CK; Miller, LL
      Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

      JOURNAL OF CLINICAL ONCOLOGY
    20. Ducreux, M; Ychou, M; Seitz, JF; Bonnay, M; Bexon, A; Armand, JP; Mahjoubi, M; Mery-Mignard, D; Rougier, P
      Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

      JOURNAL OF CLINICAL ONCOLOGY
    21. Herben, VMM; Panday, VRN; Richel, DJ; Schellens, JHM; van der Vange, N; Rosing, H; Beusenberg, FD; Hearn, S; Doyle, E; Beijnen, JH; Huinink, WWT
      Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer

      JOURNAL OF CLINICAL ONCOLOGY
    22. Gelderblom, HAJ; de Jonge, MJA; Sparreboom, A; Verweij, J
      Oral topoisomerase 1 inhibitors in adult patients: Present and future

      INVESTIGATIONAL NEW DRUGS
    23. Kollmannsberger, C; Mross, K; Jakob, A; Kanz, L; Bokemeyer, C
      Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience

      ONCOLOGY
    24. Partyka, S; Dumas, P; Ajani, J
      Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma

      CANCER
    25. Nakano, T; Chahinian, AP; Shinjo, M; Togawa, N; Tonomura, A; Miyake, M; Ninomiya, K; Yamamoto, T; Higashino, K
      Cisplatin in combination with irinotecan in the treatment of patients withmalignant pleural mesothelioma - A pilot phase II clinical trial and pharmacokinetic profile

      CANCER
    26. Cersosimo, RJ
      Irinotecan: A new antineoplastic agent for the management of colorectal cancer

      ANNALS OF PHARMACOTHERAPY
    27. HERBEN VMM; HUININK WWT; SCHELLENS JHM; BEIJNEN JH
      CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS

      Pharmacy world & science
    28. ENZINGER PC; ILSON DH; SALTZ LB; OREILLY EM; KELSEN DP
      IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES

      Oncology
    29. LILENBAUM RC; MILLER AA; BATIST G; BERNARD S; HOLLIS DR; ROSNER GL; EGORIN MJ; SCHILSKY RL; RATAIN MJ
      PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY

      Journal of clinical oncology
    30. DEJONGE MJA; SPARREBOOM A; VERWEIJ J
      THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS - A REVIEW OF PRECLINICAL AND EARLY CLINICAL-STUDIES

      Cancer treatment reviews
    31. TAKIMOTO CH; WRIGHT J; ARBUCK SG
      CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS

      Biochimica et biophysica acta, N. Gene structure and expression
    32. ARBUCK SG; TAKIMOTO CH
      AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS

      Seminars in hematology
    33. PUNT CJA
      NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA

      Cancer
    34. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    35. ROTHENBERG ML
      TOPOISOMERASE-I INHIBITORS - REVIEW AND UPDATE

      Annals of oncology
    36. ZHANG Z; INSERRA PF; LIANG BL; ARDESTANI SK; ELLIOTT KK; MOLITOR M; WATSON RR
      MELATONIN, IMMUNE MODULATION AND AGING

      Autoimmunity
    37. PANZER A; VILJOEN M
      THE VALIDITY OF MELATONIN AS AN ONCOSTATIC AGENT

      Journal of pineal research
    38. MURREN JR; ANDERSON S; FEDELE J; PIZZORNO G; BELLIVEAU D; ZELTERMAN D; BURTNESS BA; TOCINO I; FLYNN SD; BEIDLER D; CHENG YC
      DOSE-ESCALATION AND PHARMACODYNAMIC STUDY OF TOPOTECAN IN COMBINATIONWITH CYCLOPHOSPHAMIDE IN PATIENTS WITH REFRACTORY CANCER

      Journal of clinical oncology
    39. CHABOT GG
      CLINICAL PHARMACOKINETICS OF IRINOTECAN

      Clinical pharmacokinetics
    40. PANZER A
      MELATONIN IN OSTEOSARCOMA - AN EFFECTIVE DRUG

      Medical hypotheses
    41. ROWINSKY EK; KAUFMANN SH
      TOPOTECAN IN COMBINATION CHEMOTHERAPY

      Seminars in oncology
    42. SALTZ LB; KEMENY NE; TONG W; HARRISON J; BERKERY R; KELSEN DP
      9-AMINOCAMPTOTHECIN BY 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION IS INACTIVE IN THE TREATMENT OF PATIENTS WITH 5-FLUOROURACIL-REFRACTORY COLORECTAL-CARCINOMA

      Cancer
    43. DENT SF; EISENHAUER EA
      PHASE-I TRIAL DESIGN - ARE NEW METHODOLOGIES BEING PUT INTO PRACTICE

      Annals of oncology
    44. VERWEIJ J
      NEW PROMISING ANTICANCER AGENTS IN DEVELOPMENT - WHAT COMES NEXT

      Cancer chemotherapy and pharmacology
    45. JONES CA; SHAW PJ; STEVENS MM
      USE OF GRANULOCYTE-COLONY-STIMULATING FACTOR TO REDUCE THE TOXICITY OF SUPER-VAC CHEMOTHERAPY IN ADVANCED SOLID TUMORS IN CHILDHOOD

      Medical and pediatric oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 11:08:46